Biotech

All Articles

Lilly posts more good data on its once a week blood insulin possibility

.On the heels of an FDA being rejected for its chief competing Novo Nordisk, Eli Lilly is pushing on...

IN 8bio halts phase 2 test, lays off one-half of staff

.Only a couple of months after application the 1st patient in a period 2 trial for freshly identifie...

Lilly, Haya ink $1B biobuck weight problems pact to explore black genome

.Eli Lilly's look for excessive weight targets has led it to the darker genome. The Big Pharma has p...

ArsenalBio elevates $325M, pivots out of past lead possession

.Collection Biosciences is actually proceeding up. The tissue treatment provider has added $325 thou...

Lilly- backed weight loss biotech reports IPO

.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has submitted ...

Aelis' marijuana make use of medication flunks phase 2b, steering Indivior to re-think $100M option

.Aelis Farma's hopes of protecting a simple, positive selection on a $one hundred million option rep...

ProKidney stops period 3 trial not needed to have for cell therapy approval

.ProKidney has actually ceased among a pair of phase 3 tests for its tissue therapy for kidney healt...

Vaxcyte rises on 'spectacular' 31-valent PCV win versus Pfizer

.Vaxcyte unveiled what experts named "sensational" stage 1/2 information for its 31-valent pneumococ...

Recursion's brain health condition trial presents insufficient proof of efficiency

.Recursion has discovered by means of an early test of its own tech-enabled strategy to medication r...

Acepodia, Pfizer click with each other for chemistry-based tissue treatment

.Contact it a scenario of excellent chemistry: Acepodia, a biotech based on Nobel Prize-winning scie...